Calpeptin

Catalog No.S7396

For research use only.

Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively. Calpeptin attenuates apoptosis and intracellular inflammatory changes in muscle cells.

Calpeptin Chemical Structure

CAS No. 117591-20-5

Selleck's Calpeptin has been cited by 19 publications

Purity & Quality Control

Choose Selective Cysteine Protease Inhibitors

Biological Activity

Description Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively. Calpeptin attenuates apoptosis and intracellular inflammatory changes in muscle cells.
Targets
Calpain II (porcine kidney) [1] Calpain I (human platelets) [1] Calpain I (porcine erythrocytes) [1] Papainb [1]
34 nM(ID50) 40 nM(ID50) 52 nM(ID50) 138 nM(ID50)
In vitro

Calpeptin inhibits 20K phosphorylation in a dose-related manner in platelets stimulated by thrombin, ionomycin or collagen. [1] In differentiating PC12 cells, Calpeptin promotes neurite elongation via inhibition of Calpain activity. [2] In rat retinal ganglion cells, Calpeptin attenuates apoptosis, maintains normal whole-cell membrane potential, and thus provides functional neuroprotection. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PC12 MWjBeZRweGijZ4mgZZN{[Xl? MUOxNEB2VQ>? MnrBPVYhcHK| NYG0[Yo5UW6mdXP0bY9vKG:oIHH1eI9xcGGpeTDpckB2dmSrZn\ldoVvfGmjdHXkJJJifCC|dHHicIUhcW6mdXPpZoxmKFCFMUKgZ4VtdHNiZYjwdoV{e2mwZzDFS2ZRNUiGUUe0JIF{e2W|c3XkJIF{KEWJRmCtTGRSPzRiY3zlZZJidmOnIHH0JFExKHWPIHHmeIVzKDl4IHjyd{BjgSClYXzwZYlvKGGldHn2ZZRqd25iYYPzZZk> MoXDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh|OUG5OFkoRjF6M{mxPVQ6RC:jPh?=
PC12 NWjtcnY5SXW2b4DoZYd6KGG|c3H5 MXSxNEB2VQ>? M1fLRVk3KGi{cx?= MU\JcoR2[3Srb36gc4Yh[XW2b4DoZYd6KGmwIHTp[oZmemWwdHnheIVlKHKjdDDzeIFjdGViaX7keYNq[mynIGDDNVIh[2WubIOg[ZhxemW|c3nu[{BCPTOWIHHsdIhiNXO7boXjcIVqdiCjc4Pld5Nm\CCjczDBOVNVKGGucHjhMZN6dnWlbHXpckBkdGWjcnHuZ4Uh[XRiMUCgeW0h[W[2ZYKgPVYhcHK|IHL5JINidHCjaX6gZYN1cX[jdHnvckBie3OjeR?= Mn\jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh|OUG5OFkoRjF6M{mxPVQ6RC:jPh?=
COS7 MWPBeZRweGijZ4mgZZN{[Xl? NYDpNIVSPTBidV2= MlzqOFghcHK| M1zlOmlv\HWldHnvckBw\iCjdYTvdIhi\3liaX6gZYZzcWOjbjDndoVmdiCvb37r[ZkhS0:VNzDj[YxteyCneIDy[ZN{cW6pIFXHSnAuUESTN{SgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDQUGMu\XC|aXzvckBwfmW{ZYjwdoV{e2mxbj3pcoR2[2WmIFXHSnAuUESTN{SgZYdoemWpYYTpc44h[XRiNUCgeW0h[W[2ZYKgOFghcHK| NWO0UnFtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizPVE6PDlpPkG4N|kyQTR7PD;hQi=>
PC12 MXfBeZRweGijZ4mgZZN{[Xl? M4DaelExKHWP NEjQRlg6PiCqcoO= NHTZUHFKdmS3Y4Tpc44hd2ZiYYX0c5Bp[We7IHnuJJVv\GmoZnXy[Y51cWG2ZXSgdoF1KHO2YXLs[UBqdmS3Y3nicIUhWENzMjDj[YxteyCneIDy[ZN{cW6pIFG1N3Qh[WyyaHGtd5lvfWOuZXnuJIF{e2W|c3XkJIF{KEF3M2SgZYxxcGFvc4nueYNt\WmwIHPs[YFz[W6lZTDheEAyOCC3TTDh[pRmeiB7NjDodpMh[nliY3HsdIFqdiCjY4TpeoF1cW:wIHHzd4F6 MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDN7MUm0PUc,OTh|OUG5OFk9N2F-
PC12 MXnBeZRweGijZ4mgZZN{[Xl? MYKxNEB2VQ>? M2L0bFk3KGi{cx?= NF7GZWdKdmS3Y4Tpc44hd2ZiYYX0c5Bp[We7IHnuJIRq\m[ncnXueIlifGWmIILheEB{fGGkbHWgbY5lfWOrYnzlJHBEOTJiY3XscJMh\XiycnXzd4lv\yCHR1\QMWhFWTd2IHHzd4V{e2WmIHHzJGVITlBvSFTRO|Qh[2ynYYLhcoNmKGG2IEGwJJVOKGGodHXyJFk3KGi{czDifUBk[WyyYXnuJIFkfGm4YYTpc44h[XO|YYm= NUTXWmhsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizPVE6PDlpPkG4N|kyQTR7PD;hQi=>
HeLa M2XZRWF2fG:yaHHnfUBie3OjeR?= M2XDfFUxKHWP NGDB[ZBKdmS3Y4Tpc44hd2ZiYYX0c5Bp[We7IHnuJIh2dWGwIFjlUIEh[2WubIOg[ZhxemW|c3nu[{BGT0[SLVzDN{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDMR|MuOiCuZY\lcEBifCB3MDD1UUBqdiCycnXz[Y5k\SCxZjC0NFAhdk1iYnHmbYxwdXmlaX6gRVE> NF;wXpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEO5NVk1QSd-MUizPVE6PDl:L3G+
COS7 NV;2XFFuSXW2b4DoZYd6KGG|c3H5 NGS5PZQ2OCC3TR?= MXSyOEBpenN? MlTYTY5lfWO2aX;uJI9nKGG3dH;wbIFogSCrbjDh[pJq[2GwIHfy[YVvKG2xbnvlfUBEV1N5IHPlcIx{KGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJIF2fG:yaHHnc5NwdWViYYSgOVAhfU1iYX\0[ZIhOjRiaILzJIJ6KGWuZXP0do9vKG2rY4Lvd4NweHl? MoTuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh|OUG5OFkoRjF6M{mxPVQ6RC:jPh?=
COS7 NHnXe4JCfXSxcHjh[5kh[XO|YYm= Mkf6OVAhfU1? MlfFOFghcHK| Ml\sTY5lfWO2aX;uJI9nKGG3dH;wbIFogSCrbjDh[pJq[2GwIHfy[YVvKG2xbnvlfUBEV1N5IHPlcIx{KGW6cILld5NqdmdiRVfGVE1JTFF5ND;ybIVjKGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBGT0[SLVjEVVc1KGGpZ4Ll[4F1cW:wIHH0JFUxKHWPIHHmeIVzKDR6IHjydy=> NY\vVFhZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizPVE6PDlpPkG4N|kyQTR7PD;hQi=>
COS7 MmP1RZV1d3CqYXf5JIF{e2G7 MYS1NEB2VQ>? MYKyOEBpenN? MnPITY5lfWO2aX;uJI9nKGG3dH;wbIFogSCrbjDh[pJq[2GwIHfy[YVvKG2xbnvlfUBEV1N5IHPlcIx{KGW6cILld5NqdmdiRVfGVE1NSzNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hTUeIUD3MR|MhfmW|aXPs[UBifCB3MDD1UUBi\nSncjCyOEBpenN? MnrvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh|OUG5OFkoRjF6M{mxPVQ6RC:jPh?=
HeLa MonPRY51cX[rcnHsJIF{e2G7 NX;URoxJSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gdohqdm:4aYL1d{0yPCCrbjDI[WxiKGOnbHzzMEBKSzVyPUG3MlfPxE1w M{jZTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFkzPzB6Lze+R4hGVUKOPD;hQi=>
HeLa NF:1SFlEgXSxdH;4bYMh[XO|YYm= NVTvSm9vS3m2b4TvfIlkKGGldHn2bZR6KGGpYXnud5QhUGWOYTDj[YxteyC3c3nu[{BZXFRiYYPzZZktKFSFNUC9NlIvOc7:TT6= NVmxc4lYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTJ5MEivK|5EcEWPQly8M4E,
NMuMG NGG4bWFHfW6ldHnvckBie3OjeR?= NHLBd|gzPSC2bzC1NEB2VQ>? MVyyOEB1dyB5MjDodpM> M4LKXmlvcGmkaYTpc44hd2ZiY3HsdIFqdiCrbjDtc5V{\SCQTYXNS{Bk\WyuczDhd5Nme3OnZDDhd{B{fXCycnXzd4lwdiCxZjDUS2Zj\XSjMT3pcoR2[2WmIHPhcJBicW5iYXP0bZZqfHliYomgcYVie3W{aX7nJGZqdGGvaX6tRUBt\X[nbIOgZZQhOjVidH:gOVAhfU1iaX7jeYJifGWmIH\vdkAzPCC2bzC3NkBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ Mo\JQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVI4ODhxJ{7DbGVOSkx:L3G+
NMuMG NHvhTJBHfW6ldHnvckBie3OjeR?= NXPWTWh7OjVidH:gOVAhfU1? NVvUPGQxOjRidH:gO|IhcHK| NELiSGdKdmirYnn0bY9vKG:oIHPhcJBicW5iaX6gcY92e2ViTl31UWch[2WubIOgZZN{\XO|ZXSgZZMhe3WycILld5Nqd25ib3[gWGdH[mW2YUGtbY5lfWOnZDDFUXQh[nlibXXhd5VzcW6pIHHsdIhiNVOPQTDlfJBz\XO|aX;uJIF1KDJ3IITvJFUxKHWPIHnuZ5Vj[XSnZDDmc5IhOjRidH:gO|IhcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? Mo\hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVI4ODhxJ{7DbGVOSkx:L3G+
Assay
Methods Test Index PMID
Immunofluorescence Src / EGFR ; 29641465
In vivo In a feline right ventricular (RV) PO (RVPO) model, calpeptin (0.6 mg/kg, i.v.) blocks the activation of calpain and caspase-3, cleavage of their substrates, and cardiomyocyte programmed cell death. [4] In a rat focal cerebral ischemia–reperfusion injury model, Calpeptin reduces the neuronal apoptosis in hippocampal CA1 sector via inhibition of the expression of Caspase-3. [5]

Protocol (from reference)

Animal Research:[4]
  • Animal Models: Feline right ventricular (RV) PO (RVPO) model
  • Dosages: 0.6 mg/kg
  • Administration: i.v.

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 362.46
Formula

C20H30N2O4

CAS No. 117591-20-5
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCCCC(C=O)NC(=O)C(CC(C)C)NC(=O)OCC1=CC=CC=C1

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Calpeptin | Calpeptin supplier | purchase Calpeptin | Calpeptin cost | Calpeptin manufacturer | order Calpeptin | Calpeptin distributor